This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	HER2 (ERBB2; neu)	<p>A tumor-targeted photosensitive antibody conjugate could help treat HER2-positive ovarian cancer and other HER2-positive cancers. An anti-HER2 antibody conjugated to a photosensitive dye killed HER2-expressing human ovarian carcinoma cells following irradiation. Moreover, combining the photodynamic conjugate therapy with cisplatin killed human ovarian cancer cells at lower doses than those required for each agent individually. Future studies could include <i>in vivo</i> testing of the conjugate and investigating its potential to eliminate cancer cells that persist after surgical removal of tumors.</p> <p>SciBX 2(21); doi:10.1038/scibx.2009.873 Published online May 28, 2009</p>	Patenting and licensing status unavailable	<p>Serebrovskaya, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online May 18, 2009; doi:10.1073/pnas.0904140106</p> <p>Contact: Sergey M. Deyev, Russian Academy of Sciences, Moscow, Russia e-mail: deyev@ibch.ru</p>